ABCB1 and Miyoshi myopathy: Apparently, polymorphisms in MDR1 gene (SNPs) will also influence therapy outcome, for instance in MM patients under DAV protocol [98], and variously detected in MGUS, MM and relapsed MM tumor cells [99], however, their contribution to bortezomib resistance is not clear [98, 100].